Drug intelligence / Profile preview

INN-289

Development stage: Unknown
Lead developer: Innovate Biopharmaceuticals

Overview

INN-289 is a drug candidate being developed by Innovate Biopharmaceuticals, a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. It is currently in Phase 1 clinical trials for a subset of Crohn's disease and is also being developed for alcoholic steatohepatitis (ASH).

Beyond the preview

Go deeper on INN-289.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INN-289.

Explore the full profile